Dermata Therapeutics, Inc. Warrant

U.S. stock futures traded mixed on Tuesday as the Santa Claus rally resumed after Monday's declines. Major indices showed minimal movement with the S&P 500 and Nasdaq 100 slightly lower in premarket trading. Key movers included Fonar Corp surging 24.49% on a take-private deal announcement, TEN Holdings jumping 16.31% on a private placement, Boein...

Dermata Therapeutics (NASDAQ: DRMA) stock surged 20.10% on Wednesday following the announcement of a $12.4 million private placement offering. The company will issue 2,022,062 common shares and warrants priced at $2.04 per share, with expected gross proceeds of $4.1 million. If warrants are fully exercised, the company could raise an additional $...

Enphase Energy reported mixed Q2 results, leading to a rise in its stock price. Several other companies saw significant pre-market movements, both positive and negative, due to various news and earnings reports.

Dermata Therapeutics, Inc. (NASDAQ: DRMAW) shares are trading higher in Thursday's after-hours session after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis. What To Know: The announcement of the patent was made Thursday after market close, making it Dermata's first patent iss...